Pheiron @BIO-Europe Spring 2025

Published March 13, 2025

Pheiron will be attending the 19th annual BIO-Europe Spring conference taking place March 17-19, 2025 in Milan, Italy. The event will bring together over 3,700 leading executives from around the world to engage in over 20,000 partnering meetings, connecting leaders from academia, start-up, and scale-up biotech companies with forward-thinking investors and pharma companies.

At Pheiron, we are building a world where human health is quantitative and computable. Working at the frontier of computational medicine, AI, and genetics, we use population-scale biobanks and multi-omic data to resolve disease progression, understand disease mechanisms, and drive the next generation of therapies.

We collaborate closely with scientific teams to enhance decision-making with human evidence from the best-characterized biobanks in the world. We work based on phased, collaborative partnerships, offering flexibility in scope and focus to drive lasting impact on the probability of pipeline success. This BioEU, our goal is to establish impactful collaborations with biopharmaceutical companies committed to transforming their R&D processes and adopting a more effective, data-centric approach to drug development.

To schedule a meeting with our co-founder & CEO, register today. We look forward to meeting you in Milan!

ABOUT BIO-EUROPE SPRING
Over the years, BIO-Europe Spring has become Europe’s largest springtime partnering event. Its international reach makes it a one of a kind offering and gateway to the global life science community. The event will cater to the needs of the entire value chain, start-up and innovator educational programmes, industry trends and outlooks from KOLs, company pitches, professional partnering meetings as well as various networking opportunities are part of the ROI proven feature set. BIO-Europe Spring is produced by EBD Group with the support of the Biotechnology Innovation Organization (BIO).

Connect with us before the event on LinkedIn.

Align between targets, assets and populations.

Subscribe to our blog and stay tuned on Predictive Evidence in drug development.